Kornimate/medical-research-clean huggingface dataset:
itbs-neurosplasticity for female youth with depression

Conditions: Depressive Disorder

Summary: tbc

tbs

Eligibility criteria:
inclusion criteria: 1. are assigned female sex at birth; 2. are 14yo to 24yo; 3. outpatients; 4. are competent to assent (those age 14-18) or consent to participate (those age 19-24); 5. have a diagnostic and statistical manual of mental disorders fifth edition (dsm 5) diagnosis of major depressive episode by mini-international neuropsychiatric interview (mini) version 7.0.0 for participants aged 18-24 and adolescents (mini-kid) for participants aged 14-17; 6. have a score ≥ 18 on the hamilton depression rating scale (hdrs-17 item) or depressive symptom severity as shown by a total children's depression rating scale revised (cdrs-r) score 40; 7. have not changed dose or initiated a new regular antidepressant or antidepressant augmentation treatment(s) for 4 weeks prior to starting tms treatment; 8. are able to adhere to the treatment schedule; 9. pass both the tms and mri adult safety screening questionnaires. exclusion criteria: 1. have moderate or severe substance use disorder (except tobacco) within the last three (3) months; 2. have a concomitant major unstable medical illness; 3. have active suicidal intent; 4. have not responded to 2 or more adequate trials of antidepressant medication in the current episode as meassured by the athf form 5. are pregnant or planning to become pregnant during the study period; 6. have a lifetime (mini) diagnosis of any psychotic disorder; 7. have a mini anxiety disorder or personality disorder assessed by a study investigator to be primary and causing greater impairment than mde; 8. have previously had ect or rtms; 9. have any significant neurological disorder or any significant head trauma with clear radiological evidence of cerebrovascular injury on imaging. 10. have any intracranial implant (e.g., aneurysm clips) or any other metal object within or near the head, excluding the mouth, that cannot be safely removed; 11. have history of epilepsy 12. are participating in standardized regular psychotherapy provided by a psychiatrist or a registered psychologist for less than 3 months prior to study entry or planning to start during the course of rtms treatments; 13. have a clinically significant laboratory abnormality, in the opinion of the one of the principal investigators; 14. have a non-correctable clinically significant sensory impairment (i.e., cannot hear well enough to cooperate with interview);
me-wel: ehealth behaviour change intervention for weight management in post-menopausal women

Conditions: Subjective Well-being; Weight Loss; Self Esteem; Physical Activity; Eating Behavior; Behavior and Behavior Mechanisms

Summary: in post-menopause, most women gain weight, and obesity rates are more prevalent in this particular group. in addition, there is an increased risk of cardiovascular disease, cancer, and diabetes. given that this weight gain can be related to risk behaviours, healthy weight management (such as an increase in physical activity or healthy eating) is crucial to promote a healthy weight and well-being. the me-wel (menopause and weigth loss) project (ref. sfrh/bd/144525/2019), entails an ehealth intervention for weight management and well-being in post-menopausal women with overweight or obesity, based on two theoretical models of behavioral change - the health action process approach (hapa), and the health belief model (hbm), and applying the behaviour change techniques (bct) taxonomy and oxford food and activity behaviors (oxfab) taxonomy. this group's ehealth intervention lasts 8 weeks. each week there is a different theme to be addressed, taking into account the behavioral change models mechanisms, in articulation with different bct´s and weight strategies. subjective well-being, self-esteem, weight loss, implementation of weight management strategies, and changes in eating behavior and physical activity/exercise were evaluated, through follow-ups at 3- and 6- post-intervention.


Eligibility criteria:
inclusion criteria: * age (45-65 years); * post-menopausal women (which starts after menopause/last period, confirmed by 12-month amenorrhea); * women with a body mass index (bmi) of 25 kg/m2 or more (overweight) or women with a bmi of 30 kg/m2 or more (obesity); * nationality (portuguese or dual nationality); exclusion criteria: * specifical diseases and/or medical reasons to limit activity (stroke, cancer, diabetes, heart disease, epilepsy, musculoskeletal problems that severely compromise mobility; loss of functional ability); * diagnosis of mental health illness or recent hospitalization for mental health reasons; * history of alcohol dependence; * history of addiction to illicit substances; * suicidal ideation
effect of n-acetylcysteine (nac) on hydrogen sulfide (h2s) in chronic kidney disease (ckd)

Conditions: Chronic Kidney Disease; Chronic Kidney Failure; End Stage Kidney Disease; End Stage Renal Disease

Summary: cardiovascular morbidity and mortality is high in ckd patients. nitric oxide (no) deficiency plays a crucial role in progression of ckd. this leads to endothelial dysfunction, hypertension, and inflammation. hydrogen sulfide (h2s) could serve as a backup mechanism for no deficiency in ckd. n-acetylcysteine (nac) is a derivate of cysteine and this is the main substrate for h2s production. therefore, nac should enable us to stimulate h2s production in humans. our objective is to investigate the effect of nac on plasma h2s levels and on markers of oxidative stress, inflammation, and endothelial dysfunction in healthy volunteers, ckd patients, and dialysis patients. we hypothesize that there is an increase in h2s levels after treatment with nac.


Eligibility criteria:
inclusion criteria: healthy volunteers: * adult (\> 18 years and older) * healthy, as assessed by medical history, blood pressure, plasma creatinine, and urine dipstick * no medication use ckd patient: * adult (\> 18 years and older) * ckd stage 3-4 (gfr 15-60 ml/min) hemodialysis patient: * adult (\> 18 years and older) * hemodialysis patient peritoneal dialysis patient: * adult (\> 18 years and older) * peritoneal dialysis patient exclusion criteria: * unable to give informed consent * hypersensitivity to n-acetylcysteine * pregnancy

Keywords: chronic kidney disease chronic kidney failure end stage kidney disease end stage renal disease hydrogen sulfide n-acetylcysteine acetylcysteine
otoferlin patient registry and natural history study

Conditions: Otoferlin-related Auditory Synaptopathy; Hearing Impairment

Summary: this registry is designed to collect comprehensive information about the molecular genetic diagnoses of individuals with otoferlin-associated hearing impairment and clinical information to support a natural history study.

a patient registry, in both german and english languages, has been established for patients with hereditary hearing impairment due to variants in otoferlin (otof). the study is conducted in accordance with the current version of the declaration of helsinki. the study protocol and database structure have been approved by the ethics committee of the university medical center göttingen. main objective criterion: to increase understanding of natural history, types of genetic variants and to facilitate clinical and basic research on otoferlin-associated hearing impairment. secondary objective criterion: to improve knowledge to better characterize individuals with otoferlin-associated hearing impairment in the long term and create prerequisites for improved, patient tailored therapy and care.

Eligibility criteria:
inclusion criteria: * a molecular genetic diagnosis involving biallelic variants in otoferlin (otof) and audiometry exclusion criteria: * patients with evidence of non-otof molecular genetic diagnoses

Keywords: otoferlin patient registry natural history study
dietary treatment of infants with chylothorax

Conditions: Chylothorax

Summary: chylothorax occurs in \~3 to 5 % of infants undergoing cardiac surgery. standard treatment requires discontinuation of breast milk feeding, due to the abundance of long chain triglycerides, and transition to a medium chain triglyceride (mct) based formula. objective: to determine the effectiveness of fat-modified breast milk (mbm) for the treatment of chylothorax compared with mct-formula. hypothesis: the investigators primary hypothesis was that infants fed mbm would have more chyle drainage in the first 5 days after diagnosis compared to infants fed an mct based formula which is the current standard of care. design: infants with chylothorax were eligible. treatment infants (n=8) received mother's own milk that had been modified by removing the fat layer via centrifugation and adding mct and nutrients to provide 67 kcal/ml and 11 g/100 ml protein (mbm group). control infants (n=8) received an mct-formula (mct group). the feeding intervention was a minimum of 6 weeks after chest tube removal per the hospital for sick children standard chylothorax treatment protocol. outcome measures collected included chyle drainage from chest tubes, weight, length and head circumference measurements and estimated energy and nutrient intake.


Eligibility criteria:
inclusion criteria: * infants \< 12 months of age who were diagnosed with chylothorax. * infants included in the intervention group (mbm) needed to have received \>80% of their enteral feeds as breast milk prior to surgery. * infants included in the control group (mct-formula) needed to have received \<80% of their enteral feeds as breast milk prior to surgery. exclusion criteria: * subjects were excluded if their diagnosis made it unlikely that they would be able to follow the hospital's standard 6 week protocol for treatment of chylothorax * were receiving only parenteral nutrition at the time of diagnosis of chylothorax * primary caregiver of the baby did not have good comprehension of english.

Keywords: breast milk infants chylothorax cardiac surgery modified breast milk
analgesic efficacy of bilateral superficial cervical plexus block in robot-assisted endoscopic thyroidectomy using a transaxillary approach

Conditions: Thyroid Cancer

Summary: this study was designed to investigate the analgesic effect of bilateral superficial cervical plexus block in patients undergoing robot-assisted endoscopic thyroidectomy. the investigators hypothesized that bilateral superficial cervical plexus blockade would reduce the patient's pain score by more than 10 (on a vas scale of 0\~100) compared to a placebo group and control group.


Eligibility criteria:
inclusion criteria: * asa class 1 or 2 adult patients scheduled for robot-assisted endoscopic thyroidectomy exclusion criteria: * patient refusal * bleeding diathesis * allergies to local anesthetics * patient unable to read consent form (foreigner, illiterate) * pregnant women
ergt for women engaging in nssi - an effectiveness study

Conditions: Borderline Personality Disorder; Non-suicidal Self-injury (NSSI)

Summary: the primary aim is to investigate the effectiveness of emotion regulation group therapy (ergt) for women who self-harm in ordinary psychiatric outpatient health care.


Eligibility criteria:
inclusion criteria: * nssi a minimum of three times in the last six months * meets at least three criteria for borderline personality disorder according to dsm-iv-tr * contact with an other individual therapist, psychiatrist, "case manager" or equal exclusion criteria: * insertion/withdrawal of psychopharmacological substances within two months prior to the treatment * other acute primary axis i diagnosis (e.g. anorexia nervosa) that demand treatment in first hand * bipolar disorder i or primary psychosis * current substance dependence (the last month) * current life circumstances that would hinder the treatment (i.e. ongoing domestic abuse) * insufficient swedish language skills * cocurrent treatment with mentalization based therapy (mbt) or dialectical behavioral therapy (dbt)
vbmi to increase treatment completion with mk-mk-5172/mk-8742 among veterans with active substance use disorders genotype 1 chronic hepatitis c

Conditions: Patient Adherence, Chronic Hepatitis C, Alcohol-related Disorders

Summary: this study implement a values-based motivational interviewing (vbmi) intervention to promote treatment completion with fixed dose combination (fdc) mk-5172/mk-8742 x 12 weeks among 30 veterans with substance use disorder (sud) and treatment naïve genotype 1 chronic hepatitis c virus (hcv) infection.

the investigators will conduct a prospective study of 30 veterans with treatment-naive genotype 1 chronic hepatitis c infection admitted to the substance abuse residential rehabilitation treatment program (sarrtp) at the g.v. (sonny) montgomery va medical center. enrolled veterans will be treated mk-5172/mi-8742 while receiving a 12 week values based motivational intervention to promote completion of hcv treatment. mk-5172/mk-8742 will be prescribed in accordance with the package insert.

Eligibility criteria:
inclusion criteria: 1. identified as having treatment-naïve genotype 1 chronic hcv infection; veterans who are genotype 1a must have baseline ns5a resistance testing 2. current resident of the sarrtp program 3. willing to initiate treatment with fdc mk-5172/mk-8742 during sarrtp and up to 30 days post-discharge. 4. willing to attend coordinated hcv treatment clinic visits and substance abuse aftercare visits every 2 weeks upon sarrtp discharge exclusion criteria: 1. contraindications for therapy with fdc mk-5172/mk-8742 2. unable to provide written informed consent 3. hepatocellular carcinoma or other medical condition precluding hcv treatment 4. acute hcv infection 5. prior treatment for chronic hcv 6. history of decompensated cirrhosis 7. platelet count \< 75 k/cmm and/or albumin \< 3 grams/dl 8. females and male sex partners of females who are pregnant, nursing and/or unwilling to use contraception 9. patients infected with genotype 1a who have not undergone baseline ns5a resistance testing
rituximab in treating patients with refractory or recurrent hairy cell leukemia following cladribine therapy

Conditions: Leukemia

Summary: rationale: monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. purpose: phase ii trial to study the effectiveness of monoclonal antibody therapy consisting of rituximab in treating patients with refractory or recurrent hairy cell leukemia following cladribine therapy.

objectives: * determine the rate of complete and partial remission, remission duration, and relapse free survival after treatment with rituximab in patients with refractory or recurrent hairy cell leukemia who previously received cladribine. * determine the acute and long term toxicity of rituximab in these patients. outline: this is an open-label, multicenter study. patients receive rituximab iv over several hours once a week for 4 weeks. patients are followed every 3 months for 3 years and every 6 months thereafter. projected accrual: a total of 8-25 patients will be accrued for this study within 3 years.

Eligibility criteria:
disease characteristics: * histologically proven hairy cell leukemia (hcl) * classic hcl * hairy cells in the bone marrow and/or peripheral blood which co-express cd20/cd25 or cd20/cd11c, and/or which are positive for tartrate resistant acid phophatase (trap) * prolymphocytic hcl variant * lymphoid cells in the bone marrow and/or peripheral blood with morphology intermediate between typical hairy cells and prolymphocytes, which co-express cd20/cd11c but lack cd25 expression, and which are negative for trap * progressive or recurrent disease after prior treatment with cladribine * greater than 1 month since standard dose cladribine or * greater than 3 months since low dose cladribine patient characteristics: age: * 18 and over performance status: * who 0-2 life expectancy: * at least 3 months hematopoietic: * not specified hepatic: * bilirubin no greater than 2.0 mg/dl renal: * creatinine no greater than 2.3 mg/dl cardiovascular: * no serious cardiac disease other: * no acute or chronic infection * hiv negative * no psychosis * not pregnant or nursing * no other prior or concurrent malignancy except carcinoma in situ of the cervix or basal cell or squamous cell skin cancer prior concurrent therapy: biologic therapy: * not specified chemotherapy: * see disease characteristics * recovered from prior chemotherapy endocrine therapy: * not specified radiotherapy: * not specified surgery: * not specified other: * recovered from prior therapy * no concurrent cytoreductive therapy

Keywords: progressive hairy cell leukemia, initial treatment refractory hairy cell leukemia
study of mapatumumab in combination with bortezomib (velcade) and bortezomib alone in subjects with relapsed or refractory multiple myeloma

Conditions: Multiple Myeloma

Summary: the purpose of this study is to evaluate the efficacy (disease response) and safety of mapatumumab in combination with bortezomib and bortezomib alone in subjects with relapsed or refractory multiple myeloma (mm).


Eligibility criteria:
inclusion criteria: * diagnosed with multiple myeloma that is refractory or has relapsed after treatment * measurable serum and/or urine m-protein * failed 1 or 2 prior therapies for multiple myeloma * 18 years of age or older exclusion criteria: * received more than 2 prior therapies for multiple myeloma. * previous cancer therapies (chemotherapy, biologic therapy, radiation therapy or immunosuppressants) within the last 3 weeks * received monoclonal antibodies within the last 3 weeks (chimeric or murine) or 8 weeks (human or humanized) * received investigational (not yet approved by a regulatory authority) agent to treat multiple myeloma within the last 4 weeks * subjects who received a stem cell transplant using cells from themselves in the past 16 weeks * subjects who received a stem cell transplant using cells from another individual * previously treated with bortezomib or mapatumumab * known hiv, hepatitis-b, hepatitis-c, or hepatitis a infection * infection requiring antibiotics or hospitalization within the last 2 weeks * major surgery within the last 4 weeks * diagnosis with poems syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes) * history of other cancers within the past 5 years * pregnant or breast-feeding women
multi cervical unit measures of cervical isometric strength and range of motion: a pilot study

Conditions: Cervicogenic Headache; Neck Pain; Whiplash; Kyphotic and Reversed Cervical Curves

Summary: this study is designed to collect normative data on cervical isometric strength and range of motion to supplement an existing normative data base.


Eligibility criteria:
inclusion criteria: * logan students, faculty and staff exclusion criteria: * recent surgery,or unstable or fused joints of the cervical spine * using medications, prescription or herbal muscle stimulants, relaxants, etc * previous cervical spine injury, surgery or condition that would affect your range of motion in the cervical spine * currently have any local infection, injury or other malignancy affecting the cervical spine * congenital conditions affecting the cervical spine, i.e. block vertebrae * systemic illness with an adverse effect on the cervical spine * a history of dizziness, light headedness or passing out, or any seizure disorder * had a neck, shoulder or back injury * ever been in an automobile accident * exercise regularly * pregnant * spinal manipulation mobilization or other therapy in the last 48 hours
prognostic impact of lesion-specific hemodynamic index in patients with coronary artery disease

Conditions: Coronary Artery Disease

Summary: the investigators aim to investigate the additive prognostic value of lesion-specific hemodynamic index such as δffr, non-hyperemic pressure ratio such as rfr, over % diameter stenosis and ffr according to treatment strategy, and to find the prognostic implications of post-pci ffr after adjustment of various clinical and disease characteristics, and to construct a comprehensive risk prediction model for post-pci outcomes.

fractional flow reserve (ffr)-based revascularization is the currently best practice recommended by guidelines. in addition to the use of coronary physiological indices as a vessel-specific metric, recent studies suggested the clinical importance of local hemodynamics in prediction of risk for target vessel failure or acute coronary syndrome in patients with coronary artery disease. in patients who receive percutaneous coronary intervention (pci), the absolute value and pattern of ffr change after stenting are helpful in defining the additional target for pci and risk stratification after pci. however, there has been no prospective study that proved the benefit of change in ffr across the lesion (δffr) in daily clinical practice, and ffr usage after stenting is much less than before stenting. accordingly, we will prove the benefit of δffr in addition to ffr, prognostic implications of combining rfr and ffr, and the comprehensive risk model with post-pci ffr, clinical and disease characteristics in a prospective study, to maximize the benefit of invasive physiologic assessment.

Eligibility criteria:
inclusion criteria: 1. age ≥20 years 2. all comers who underwent successful ffr measurement and pullback tracing exclusion criteria: 1. chronic renal failure (estimated glomerular filtration rate \<30) 2. st-elevation myocardial infarction within 72 hours or previous coronary artery bypass graft surgery history 3. primary myocardial or valvular disease 4. left ventricular ejection fraction \< 30% 5. hemodynamically unstable clinical conditions 6. life expectancy \< 2 years
fast track module based colonoscopy training programme for surgical trainees at north jutland surgical departments

Conditions: Harm Reduction; Perforation During Colonoscopy; Colorectal Cancer

Summary: specially educated trainers will be responsible for colonoscopy training of junior doctors. the educated trainers will have attended seminars held by valori et al. the following fast track colonoscopy training program for junior doctors will consist of: 1) endoscopy simulation training and theory course 2) supervised and partly supervised lower endoscopy. 3) directly observed practical skills according graded by mcsat (mayo clinical skills assessment tool) .

initially a "train the trainers" program will begin with 3 sessions held by valori et al. at aalborg university hospital. 6 trainers are expected to be trained during the "train the trainers" program. the doctors selected for the "train the trainers" program are doctors specialized in abdominal surgery with an extensive lower gi-endoscopy experience and who is considered to have an excellent teaching ability to educate junior doctor. the training program for junior doctors consist of the following: * initial 1 day endoscopy simulation and theory at nordsim. endoscopy simulation scores will be monitored. * 20 days of fully supervised colonoscopies (max booking of 6 colonoscopies pr day). trainer is always present in the endoscopy room * mcsat (mayo clinical skills assessment tool) will be used to grade the trainee multiple times and planned at day 0,5,10,15 and 20. multiple graders will be used. * simulator test will be held at day 0, 10 and 20 colonoscopies to validate progress and compare simulator generated measures with mcsat. both the accutouch and symbionix simulator will be used,

Eligibility criteria:
inclusion criteria: * doctors currently enrolled in pgy1, 2 and 3 - danish equivalents: introduktionsstilling, hoveduddannelse 1, 2. * able to arrange colonoscopy training in such a way that the total program can be completed in 12 weeks. * able to perform supervised upper endoscopy. exclusion criteria: * less than 4 months left at current job position.

Keywords: education training fast track colonoscopy